Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

ClinicalTrials.gov ID: NCT06293365

Public ClinicalTrials.gov record NCT06293365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Study identification

NCT ID
NCT06293365
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
155 participants

Conditions and interventions

Interventions

  • VAY736 1ml PFS Biological
  • VAY736 2 ml PFS Biological
  • VAY736 2ml AI Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 1, 2024
Primary completion
Jun 4, 2025
Completion
Jan 15, 2029
Last update posted
May 11, 2026

2024 – 2029

United States locations

U.S. sites
17
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
Pinnacle Research Group Llc Anniston Alabama 36207
Providence Medical Foundation Fullerton California 92835
Advanced Medical Research La Palma California 90623
Conquest Research Winter Park Florida 32789
Parris and Associates Rheumatology Lawrenceville Georgia 30044
Indiana Univ School of Dentistry Indianapolis Indiana 46202
Ochsner Health System Baton Rouge Louisiana 70809
Ahmed Arif Medical Research Center Grand Blanc Michigan 48439
Paramount Med Rsrch and Consult LLC Middleburg Heights Ohio 44130
RAO Research LLC Oklahoma City Oklahoma 73116
Altoona Center for Clin Res Duncansville Pennsylvania 16635
West Tennessee Research Institute Jackson Tennessee 38305
Shelby Research LLC Memphis Tennessee 38119
Novel Research LLC Bellaire Texas 77401
Southwest Rheum Rsrch LLC Mesquite Texas 75150
Uni of Texas Health Science Center San Antonio Texas 78229
Advanced Rheumatology of Houston Spring Texas 77382

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06293365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 11, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06293365 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →